R
Rebecca Dent
Researcher at National University of Singapore
Publications - 182
Citations - 13686
Rebecca Dent is an academic researcher from National University of Singapore. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 41, co-authored 159 publications receiving 9882 citations. Previous affiliations of Rebecca Dent include University of Toronto & National Center for Charitable Statistics.
Papers
More filters
Journal ArticleDOI
Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence
Rebecca Dent,Maureen E. Trudeau,Kathleen I. Pritchard,Wedad Hanna,Harriet K. Kahn,Carol Sawka,Lavina Lickley,Ellen Rawlinson,Ping Sun,Steven A. Narod +9 more
TL;DR: Triple-negative breast cancers have a more aggressive clinical course than other forms of breast cancer, but the adverse effect is transient.
Journal ArticleDOI
Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid,Javier Cortes,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Carsten Denkert,Yeon Hee Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis,Peter A. Fasching,Fatima Cardoso,Michael Untch,L. Jia,Vassiliki Karantza,Jing Zhao,Gursel Aktan,Rebecca Dent,Joyce O'Shaughnessy,Keynote Investigators +21 more
TL;DR: Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plus neoadjuvant chemotherapy than among thosewho received placebo plusNeoadjuant chemotherapy.
Journal ArticleDOI
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski,Jacek Gronwald,Tomasz Huzarski,Ewa Grzybowska,Magdalena Budryk,Małgorzata Stawicka,Tomasz Mierzwa,Marek Szwiec,Rafal Wisniowski,Monika Siołek,Rebecca Dent,Jan Lubinski,Steven A. Narod +12 more
TL;DR: A low rate of pCR was observed in women with breast cancer and a BRCA1 mutation who were treated with AT or CMF, and a high rate was seen after treatment with cisplatin.
Journal ArticleDOI
Pattern of metastatic spread in triple-negative breast cancer
TL;DR: The excess risk of distant recurrence in triple-negative breast cancers, versus other forms of cancer, is attributable in large part to an excess of visceral metastases in the first five years following diagnosis.
Journal ArticleDOI
Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design.
Farrah Kassam,Katherine Enright,Rebecca Dent,George Dranitsaris,Jeff Myers,Candi Flynn,Michael Fralick,R. Kumar,Mark Clemons +8 more
TL;DR: The duration of first-, second-, and third-line chemotherapy as a surrogate for duration of treatment response was evaluated to identify prognostic variables and revealed that age < 50 years, ALP > 120 U/L, history of previous chemotherapy, DDFI < 12 months, and visceral presentation were all independently associated with a poor prognosis.